Kerstin Lüdtke-Heckenkamp

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe et al. · Therapeutic Advances in Medical Oncology · 2020 · 46 citations · Full text

Medicine, Endocrinology, Oncology +17

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Nadia Harbeck, Peter A. Fasching, Rachel Wuerstlein et al. · Annals of Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Oleg Gluz, Sherko Küemmel, Ulrike Nitz et al. · Annals of Oncology · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer

Charles E. Geyer, Gong Tang, Valentina Nekljudova et al. · Clinical Cancer Research · 2025 · 15 citations

Medicine, Oncology, Pharmacology +17

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk et al. · The Breast · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacology +16